What are the recommended treatment medications for Helicobacter pylori infection, including first‑line therapy, alternatives for penicillin allergy, clarithromycin resistance, and rescue therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

H. pylori Treatment Medications

For treatment-naive patients, bismuth quadruple therapy (BQT) for 14 days is the preferred first-line regimen when antibiotic susceptibility is unknown, consisting of PPI (standard dose twice daily), bismuth (~300mg four times daily), metronidazole (500mg three to four times daily), and tetracycline (500mg four times daily). 1

First-Line Treatment Options

The choice of first-line therapy depends primarily on local clarithromycin resistance patterns and penicillin allergy status:

In Areas with High Clarithromycin Resistance (≥15%)

  • Bismuth quadruple therapy (PBMT) for 14 days is universally recommended by all major guidelines 2

    • PPI (standard dose) twice daily
    • Bismuth subsalicylate 262mg (2 tablets) or colloidal bismuth subcitrate 120mg four times daily
    • Metronidazole 400-500mg three to four times daily
    • Tetracycline 500mg four times daily

  • Concomitant non-bismuth quadruple therapy (PAMC) for 14 days is an alternative when bismuth is unavailable 2

    • PPI twice daily
    • Amoxicillin 1000mg twice daily
    • Metronidazole 500mg twice daily
    • Clarithromycin 500mg twice daily

In Areas with Low Clarithromycin Resistance (<15%)

  • PPI triple therapy for 14 days remains an option 2
    • PPI twice daily
    • Amoxicillin 1000mg twice daily OR metronidazole 500mg twice daily
    • Clarithromycin 500mg twice daily
    • Important caveat: This regimen is now restricted by all guidelines due to rising resistance rates

Newer FDA-Approved Alternatives (2024 Update)

  • Rifabutin triple therapy for 14 days 1

    • PPI twice daily
    • Amoxicillin 1000mg twice daily
    • Rifabutin 150mg twice daily or 300mg once daily

  • Potassium-competitive acid blocker (PCAB) dual therapy for 14 days 1

    • Vonoprazan with amoxicillin (specific dosing per product labeling)

Treatment for Penicillin Allergy

In patients with true penicillin allergy, bismuth quadruple therapy (PBMT) is the preferred first-line option 2. The Toronto Consensus specifically favors this over clarithromycin-metronidazole triple therapy based on superior efficacy 2.

Alternative regimens for penicillin-allergic patients include:

  • Minocycline-based bismuth quadruple therapy for 14 days 3

    • PPI twice daily
    • Bismuth four times daily
    • Minocycline 100mg twice daily
    • Metronidazole 400mg four times daily
    • Achieves 84-91.7% eradication rates with good tolerability

  • Cefuroxime-based bismuth quadruple therapy for 14 days (if no cross-reactivity concern) 3

    • PPI twice daily
    • Bismuth four times daily
    • Cefuroxime 500mg twice daily
    • Metronidazole 400mg four times daily

Critical pitfall: Many patients who report penicillin allergy do not have true allergy. After first-line treatment failure, the ACG recommends allergy testing before proceeding with second-line therapy, as this may expand treatment options 4, 2.

Second-Line (Rescue) Therapy

After one failed treatment attempt, the choice is between bismuth quadruple therapy and levofloxacin triple therapy, depending on what was used previously 2.

If First-Line Was NOT Bismuth Quadruple Therapy

  • "Optimized" bismuth quadruple therapy for 14 days 1
    • Same regimen as above but ensuring optimal dosing and adherence

If First-Line WAS Bismuth Quadruple Therapy

  • Levofloxacin triple therapy (PAL) for 14 days 2

    • PPI twice daily
    • Amoxicillin 1000mg twice daily
    • Levofloxacin 500mg once daily or 250mg twice daily

  • Rifabutin triple therapy for 14 days 1

    • Preferred empiric salvage option in the 2024 ACG guidelines

Key principle: Never re-use clarithromycin or levofloxacin after failure, as resistance develops rapidly after exposure 2. Metronidazole can be re-used with bismuth due to synergistic effects. Amoxicillin and tetracycline can be re-used as resistance remains rare 2.

Third-Line and Beyond (Refractory Infection)

After two failed therapies with confirmed adherence, antibiotic susceptibility testing should be performed to guide subsequent regimens 4, 1.

If susceptibility testing is unavailable:

  • High-dose dual therapy for 14 days 2

    • Rabeprazole 20mg four times daily OR other PPI at double standard dose twice daily
    • Amoxicillin 750mg four times daily (total 3g/day in 3-4 divided doses)

  • Rifabutin triple therapy for 10-14 days 4, 2

    • PPI twice daily
    • Amoxicillin 1000mg twice daily
    • Rifabutin 150-300mg daily
    • Reasonable to use without susceptibility testing since rifabutin and amoxicillin resistance are rare 4

  • Levofloxacin quadruple therapy for 10-14 days (if susceptibility confirmed) 4

    • PPI twice daily + levofloxacin + 2 other antibiotics based on susceptibility

Critical Treatment Principles

Duration

14 days is the preferred duration for all first-line therapies 2. While 10-14 days may be acceptable for some quadruple therapies if proven locally effective, the consensus favors 14 days to maximize first-attempt success 2.

Acid Suppression

  • Standard PPI doses: pantoprazole 40mg, lansoprazole 30mg, omeprazole 20mg, esomeprazole 20mg, dexlansoprazole 30mg, rabeprazole 20mg 4
  • Optimal timing: 30 minutes before eating on an empty stomach 4
  • High-dose PPI (double standard dose) may improve eradication in certain regimens 5
  • Vonoprazan (PCAB) provides more potent acid suppression than PPIs 5

Antibiotic Resistance Patterns

Rising resistance is the primary driver of treatment failure:

  • Clarithromycin resistance: >30% in many regions 6, 1
  • Levofloxacin resistance: >30% in many regions 6, 1
  • Metronidazole resistance: >30% in many regions 6, 1
  • Amoxicillin and tetracycline resistance: remains rare 4, 2

Adjunctive Therapies

Probiotics are of unproven benefit for refractory H. pylori and should be considered experimental 4. However, they may reduce antibiotic-associated adverse events 5.

Common Pitfalls to Avoid

  1. Using clarithromycin-based triple therapy in high-resistance areas - This is the most common error leading to treatment failure
  2. Prescribing <14 days for first-line therapy - Shorter durations compromise eradication rates
  3. Re-using clarithromycin or levofloxacin after failure - Resistance develops rapidly after exposure
  4. Not confirming adherence before declaring treatment failure - Poor compliance is a major cause of apparent treatment failure
  5. Failing to obtain susceptibility testing after two failures - This is when empiric therapy becomes unreliable 4, 1

Local Data Importance

Compiling and making publicly available local H. pylori eradication success rates for each regimen is critical for guiding treatment selection 4. Treatment should be tailored to local resistance patterns when known.

References

1
Research

ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.

The American journal of gastroenterology, 2024

5
Research

Management of Helicobacter pylori infection.

JGH open : an open access journal of gastroenterology and hepatology, 2023

Related Questions

What is the appropriate first-line treatment regimen for H. pylori infection in an adult patient without drug allergies, prior therapy, or pregnancy?
What is the recommended treatment regimen for a 13‑year‑old patient with confirmed Helicobacter pylori infection, including dosing and alternatives for penicillin allergy or clarithromycin resistance?
What is the recommended second‑line regimen for a patient with Helicobacter pylori infection who cannot take penicillin or metronidazole and has not previously received levofloxacin?
Should household contacts of a patient with Helicobacter pylori infection be treated?
What is the recommended diagnosis and management for persistent Helicobacter pylori infection after initial eradication therapy?
What is the optimal time of day to take ritlecitinib (once daily)?
In a patient with new‑onset presyncope, supraventricular tachycardia episodes, and metoprolol therapy, what electrocardiogram changes indicate pre‑excitation?
In a patient with new‑onset presyncope, documented supraventricular tachycardia episodes, and pre‑excitation on the resting electrocardiogram while taking metoprolol, is there any role for a stress (exercise) electrocardiogram?
What specific type of knee immobilizer should I use?
Is a conjugated bilirubin level of 3.5 µmol/L normal for a patient who previously had an elevated direct bilirubin of 4.1 mg/dL, and what further management is indicated?
Should a patient with a rheumatoid factor of 42.2 IU/mL be referred to rheumatology, and what other conditions can cause an elevated rheumatoid factor?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.